ÂÜÀòÂÒÂ×

Andrew Levitch is an innovative, results-driven executive with significant experience leading strategic, financial, and operations teams in life sciences and technology companies (Biotech, precision medicine, clinical decision support, patient engagement, medical device, diagnostic, real-world evidence, manufacturing), ranging from Fortune 50 to venture-backed startups. Mr. Levitch has held CEO, CFO, and COO roles for several Private Equity and Venture-backed companies as well as Board member/observer positions. Mr. Levitch has implemented operational efficiencies that have led to millions in annual savings and have been involved in raising over $200 million in equity and debt financing, as well as exit strategy development and execution. Mr. Levitch has been a highly regarded advisor to the Merck Global Health Innovation Fund, a $500M Evergreen Venture Fund. Mr. Levitch has served on the Board of Directors of a genomic information company and a medical imaging company focused on providing imaging services for clinical trials (now acquired). Earlier he was Senior Director, Global Scientific Strategy, Portfolio Management at Merck & Co. and was responsible for the integration and analysis of internal and external business and scientific data to evaluate early R&D choices with the goal of maximizing the probability of achieving Merck’s pharmaceutical portfolio objectives. Mr. Levitch received an MBA from Lehigh University College of Business and a BS from Rutgers College Business School.